Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Treatment of vaginal candidiasis,Oropharyngeal and esophageal candidiasis,Candidal urinary tract infections, peritonitis, and systemic infections including candidemia, disseminated candidiasis, and pneumonia,Prophylaxis in bone marrow transplant recipients with chemotherapy or radiation therapy,Cryptococcal meningitis and cryptococcosis at other sites
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
400 mg IV on day 1, then 200 mg IV once daily
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal elimination half-life is approximately 30 hours (range 20–50 hours) in adults; prolonged in renal impairment. In neonates, half-life is longer (up to 90 hours).
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Fluconazole is primarily metabolized by the liver, with approximately 11% of the dose metabolized; the unchanged drug is the major circulating entity. Hepatic metabolism involves N-oxidation and glucuronidation, but specific CYP enzymes are not significantly involved. It is a moderate inhibitor of CYP2C9 and CYP3A4.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Primarily renal; approximately 80% of the dose is excreted unchanged in urine. Minor biliary/fecal elimination (<10%).
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Approximately 11–12% bound to plasma proteins (mainly albumin).
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Approximately 0.7 L/kg, indicating extensive distribution into total body water; penetrates well into tissues and CSF.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Oral bioavailability is >90% (virtually complete). IV administration is 100%.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
For Cr Cl 50-90 m L/min: no adjustment; Cr Cl 10-49 m L/min: 50% dose or interval doubling; Cr Cl <10 m L/min (not on dialysis): 50% dose or interval doubling; on hemodialysis: one full dose after each dialysis session
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific dose adjustment for Child-Pugh A or B; caution in severe hepatic impairment (Child-Pugh C) with monitoring
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Loading dose: 12 mg/kg IV (max 400 mg) on day 1, then 6 mg/kg IV (max 200 mg) once daily; for weight <40 kg, adjust based on weight using these mg/kg doses
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Dose based on renal function; no specific age-related adjustment beyond renal considerations
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
No FDA black box warning.
None
Hepatic toxicity: severe liver injury including fatal cases; discontinue if signs of liver disease develop,Anaphylaxis and allergic reactions,QT prolongation and torsade de pointes; use with caution in patients with proarrhythmic conditions,Adrenal insufficiency: fluconazole may inhibit adrenal steroidogenesis,Fetal harm: use during pregnancy only if benefit outweighs risk; multiple congenital anomalies reported,Skin reactions: monitoring for exfoliative disorders
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to fluconazole, azole antifungals, or any component of the formulation,Concomitant use with drugs that are CYP3A4 substrates with QT prolongation potential (e.g., cisapride, pimozide, quinidine, erythromycin, certain statins) due to risk of serious cardiac arrhythmias,Caution in patients with hepatic impairment, pregnancy, and breastfeeding
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No significant food interactions with IV formulation. Oral fluconazole absorption is not affected by food. Avoid grapefruit juice? Not specifically contraindicated, but grapefruit juice may rarely affect CYP3A4 metabolism; no documented interaction with fluconazole.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
First trimester: Multiple case reports and epidemiological studies suggest an increased risk of spontaneous abortion and congenital anomalies, particularly craniofacial and skeletal malformations, with high-dose (400-800 mg/day) fluconazole exposure. Low-dose (150 mg single dose) exposure is not consistently associated with increased risk. Second and third trimesters: Standard doses are not associated with teratogenic risk, but prolonged high-dose therapy may increase risk of preterm birth and low birth weight.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Fluconazole is excreted into human breast milk with a milk-to-plasma ratio (M/P) of approximately 0.9-1.0. Concentrations in milk are similar to maternal plasma. After a single 150 mg dose, the infant dose is estimated at 2-3 mg/kg/day, which is less than the neonatal therapeutic dose. The American Academy of Pediatrics considers fluconazole compatible with breastfeeding, but caution is advised with prolonged high-dose therapy.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy does not significantly alter fluconazole pharmacokinetics; however, increased volume of distribution and enhanced clearance may occur, potentially requiring higher doses for severe infections. For systemic mycoses, standard dosing is generally used. For vaginal candidiasis, a single 150 mg oral dose is effective. For cryptococcal meningitis in pregnancy, recommended maintenance dose is 200-400 mg daily after loading dose (400 mg). Monitor therapeutic response and adjust dose based on clinical efficacy and local resistance patterns.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
DIFLUCAN (fluconazole) in 0.9% sodium chloride is an IV formulation for patients unable to take oral. Monitor renal function and adjust dose if Cr Cl <50 m L/min. Caution with hepatotoxic drugs; check LFTs. QTc prolongation risk: avoid with other QTc-prolonging agents and electrolyte abnormalities. Transition to oral fluconazole when feasible. Incompatible with amphotericin B and other drugs; use separate lines.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Do not mix with other medications in the same IV line.,Report any signs of liver problems (yellowing skin/eyes, dark urine, severe nausea) or irregular heartbeat.,Complete the full course even if feeling better.,May cause dizziness; avoid driving if affected.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 400 mg IV on day 1, then 200 mg IV once daily. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. First trimester: Multiple case reports and epidemiological studies suggest an increased risk of spontaneous abortion and congenital anomalies, particularly craniofacial and skeleta. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.